Recruiting Multiple Myeloma Studies in Beijing
A Study of Daratumumab
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research a...
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \[DM\] or polymyositis \[PM\]). Idiopath...
About Multiple Myeloma Clinical Trials in Beijing
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Beijing, BEIJING%20MUNICIPALITY. These studies are seeking a combined 711 participants. Research is being sponsored by Janssen Research & Development, LLC, Pfizer. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Beijing — FAQ
Are there multiple myeloma clinical trials in Beijing?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Beijing, BEIJING%20MUNICIPALITY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Beijing?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beijing research site will contact you about next steps.
Are clinical trials in Beijing free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beijing studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Beijing are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov